We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multicancer Blood Test Aids Screen for Cancer Guide Intervention

By LabMedica International staff writers
Posted on 12 May 2020
As minimally invasive screening tests, liquid biopsies could help reduce cancer-specific morbidity and mortality through earlier detection. More...
However, there is debate on how to effectively screen large populations for cancer, including individuals who do not have symptoms or history of the disease.

A minimally invasive, multicancer blood test demonstrated utility for screening and helping to guide management of individuals with no cancer history, according to results of a prospective study. Use of the test, which can be incorporated safely into routine clinical care, could lead to surgery with curative intent among asymptomatic individuals.

A large team of scientists mainly from Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) analyzed the multicancer, multianalyte screening DETECT-A blood test, which incorporated DNA and protein markers, among 10,006 women aged 65 to 75 years with no prior history of cancer which is a population with a high degree of compliance with standard-of-care screening. Women with a positive DETECT-A result received an imaging test, usually positron emission tomography–computed tomography (PET-CT), to localize the putative cancer.

The blood test effectively identified women with multiple types of cancer, with a positive predictive value higher than existing noninvasive screening tests for individual cancers. No screening tests exist for seven of the 10 different types of cancer identified by DETECT-A. Overall, blood testing detected 26 different cancers. Of these, 15 underwent PET-CT imaging and nine were surgically excised. Twenty-four additional cancers were detected by standard-of-care screening and 46 by neither approach. One percent of participants underwent PET-CT imaging based on false-positive blood tests, and 0.22% underwent a futile invasive diagnostic procedure. Nearly two-thirds (65%) of cancers detected by the test were considered local or regional disease. The most common alterations identified in plasma included somatic mutations in TP53, BRAF, KRAS and PIK3CA.

Nickolas Papadopoulos, PhD, a Professor of Oncology and Pathology and senior author of the study, said, “The DETECT-A study incorporated PET-CT imaging to provide independent confirmation of the existence of a cancer and to precisely localize its site. For example, we could detect a lung cancer, tell in which lobe of which lung the cancer was located, the size of the cancer and if there were metastatic lesions present. Blood tests alone are not able to provide this type of precise information.” The study was published on April 28, 2020 in the journal Science.

Related Links:
Johns Hopkins Kimmel Cancer Center


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.